Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

96-week, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

NCT07715084 is registered in ClinicalTrials.gov with Azafaros B.V. as lead sponsor.

NCT NCT07715084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07715084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
96-week, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
Lead sponsor
Azafaros B.V.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 28, 2026
Completion date
July 31, 2029
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease type 3